Proteins that guide transcription factors from the nuclear membrane to the DNA cause drug-resistant skin cancers and are new targets for drug development.
A decades-long scientific collaboration points the way to therapies for "chemo brain," the cognitive impairment that follows cancer treatment.
Stanford and SLAC researchers are developing new technology to dramatically reduce the duration of radiation therapy and its treatment side effects.
The leading cause of death in the U.S. is shifting from heart disease to cancer at varying paces across the country, according to Stanford research.
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.
A Stanford team has developed an algorithm that uses data about tumors to identify new classifications that can provide information about patient outcomes
A Stanford-designed computer algorithm helps doctors predict the lifespan of patients with metastatic cancer by looking for clues in their own exam notes.
In a new study, a team of researchers has examined the relationship between protein binding to DNA and the development of cancer.
A new generation of brain cancer patients are working to improve care and connect and support patients using social media and advocacy.
Stanford researchers have learned that cancer cells can batter their way into new territory, rather than relying on dissolving chemicals.
Cancerous tumors cause disease in two ways: they grow and spread. But a new immune therapy approach may be able to target both problems simultaneously.
A better understanding of how nanoparticles move from the bloodstream into a tumor could eventually lead to more effective cancer treatment.
In this essay that originally appeared in Months to Years, writer Mal Schoen describes how he was diagnosed with colon cancer.
Hiding mRNA messages in CARTs — positively charged degradable vehicles —smuggles them across the cell membrane and can 'vaccinate' against cancer in mice.
Online outreach and low-cost testing can encourage relatives of cancer patients to assess their own cancer risk through 'cascade' testing.
Mapping the geography of the immune response in triple negative breast cancers predicts patient survival and sheds light onto new aspects of tumor biology.